Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open‐label, single‐arm, phase 3, and postmarketing clinical study

INTRODUCTION: Adenosine deaminase (ADA) deficiency is an ultrarare inherited purine metabolism disorder characterized by severe combined immunodeficiency. Elapegademase‐lvlr is a new pegylated recombinant bovine ADA used in enzyme‐replacement therapy (ERT) for ADA deficiency. Therefore, replacement...

Descripción completa

Detalles Bibliográficos
Autores principales: Onodera, Masafumi, Uchiyama, Toru, Ariga, Tadashi, Yamada, Masafumi, Miyamura, Takako, Arizono, Hironori, Morio, Tomohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367445/
https://www.ncbi.nlm.nih.gov/pubmed/37506145
http://dx.doi.org/10.1002/iid3.917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367445/
https://www.ncbi.nlm.nih.gov/pubmed/37506145
http://dx.doi.org/10.1002/iid3.917

Ejemplares similares